

G. Pio^a (Dr), T. Feola^{*b,c} (Dr), L. Rostomyan^d (Dr), G. Vitrani^b (Dr), P. Petrossians^d (Prof),

A. Beckers^d (Prof), A. Romigi^b (Dr), ML. Jaffrain-Rea^{a,b} (Prof)

^a University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences, L'Aquila, Italy ; ^b Neuromed Institute, IRCCS, Pozzilli (is), Italy ; ^c Sapienza University of Rome, Department of Experimental Medicine; ^d Centre Hospitalier Universitaire de Liège, Department of Endocrinology, Liege, Belgium

INTRODUCTION

The Obstructive Sleep Apnea (OSA) syndrome is highly prevalent in acromegaly (≈ 80%) and often persists after disease remission. We report a series of acromegalics in whom nocturnal Continuous Positive Airway Pressure (CPAP) ventilation therapy was indicated on the basis of standard criteria (Ref.1) and compare OSA severity, co-morbidities and the impact of CPAP with a control group.


PATIENTS AND METHODS:


Thirty acromegalic patients (ACRO) - 22/30 with an active disease - were compared to 30 control OSA patients (CTRL) matched for age, gender, and BMI. Each group included 21 M, 9 F, median age 53.5 yrs in ACRO vs 54.5 yrs in CTRL (P ns). Hypertension (HT) and diabetes mellitus (DM) were recorded. After CPAP was indicated on the basis of basal home-sleep apnea test or polysomnography, a second sleep study was available in 21 ACRO - 6/21 with an active disease. Continuous data are expressed as median (range) and analysed by non-parametric tests, percentages were compared by the Chi-square test. P<0.05 was considered significant.

RESULTS

Data obtained at baseline are summarized in **Table 1**. At baseline, ACRO and CTRL had a similar prevalence of severe OSA (23/30 each, 76.6%) and AHI was not significantly higher in ACRO than in CTRL (44.7 vs 35.1 AHI/h, P ns). In contrast, HT and DM were significantly more prevalent in ACRO than in CTRL (P=0.012 for HT; P<0.001 for DM). Data obtained at second sleep evaluation in 21 ACRO (14 on CPAP) and matched CTRL patients (all on CPAP) are summarized in **Table 2** and **Table 3**. A remarkable improvement was observed in both groups (median AHI decrease -86.4% in ACRO vs -87.8% in CTRL, P ns). However, the best results were obtained in the ACRO-CPAP subgroup (median AHI decrease -93.9% P ns). In acromegalics, AHI decrease (% of baseline) was also significantly correlated with the decrease in BMI (P = 0.041) and tended to be correlated with the decrease in IGF1 (P = 0.07).

Table 1 : Comparison of OSA severity in ACRO and CTRL					Table 3	Table 3: Efficacy of treatment in ACRO on CPAP and CTRL				
	1rst evaluation	ACRO (n=30)	CTRL (n=30)	Ρ			ACRO-CPAP (n=14)	CTRL (n=14)	Р	
1	Age (yrs)	53.5 [28-72]	54.5 [31-68]	p=1.000	AH	l post CPAP	3.1 [0.7-41]	5.4 [0.2-19]	p=0.198	
	BMI (Kg/m ²)	30.6 [22-42.3]	30.8 [24.7-43.4]	p=0.971	% s	severe OSA	1/14 [7.1%]	0/14 [0%]	p=0.309	
	Hypertension	26/30 [86.7%]	16/28 [57.1%]	p=0.012	AF	II decrease	93.9 % [30.7-98.7]	89.4 % [49.8-99.6	6] p=0.541	
	Diabetes Mellitus	13/30 [43.3%]	1/28 [3,6%]	P<0.001	Graphi	Graphic 1: Correlation between AHI decrease and BMI decrease				
	IGF1 (% ULN)	169.2 [30.7-399.5]	_		30 -			٠		
	AHI	44.7 [14.8-93.4]	35.1 [17.1-106.5]	p=0.423	20 -			rh	o = -0.532	
	% severe OSA	23/30 [76.7%]	23/30 [76.7%]	p=1.000	%				= 0.041	
т	Table 2: Efficacy of treatment in ACRO and CTRL							•		
	2° evaluation All ACRO (n=21) CTRL (n=21)			Ρ	BMI de	•	• •			
					ш ,			•		





p=0.396

33.6 [17.1-82.1]

CONCLUSIONS

Compared to OSA patients with similar demographics and BMI, no clear increase in OSA severity was observed in ACRO. However, comorbidities were more severe, which is a further indication to actively treat OSA. Because the control of acromegaly may not be sufficient to control OSA and the best results were obtained in acromegalics receiving CPAP, ventilation therapy should be considered early in the management of acromegaly.

References: 1. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-1394. doi: 10.1378/chest.14-0970. PMID: 25367475.

The author has declared no conflict of interest.

IGF1 (% ULN)

AHI post

99.9 [14.3-204]

46.3 [14.8-93.4]